Literature DB >> 17570246

Low serum adiponectin is associated with high circulating oxidized low-density lipoprotein in patients with type 2 diabetes mellitus and coronary artery disease.

Riikka Lautamäki1, Tapani Rönnemaa, Risto Huupponen, Terho Lehtimäki, Patricia Iozzo, K E Juhani Airaksinen, Juhani Knuuti, Pirjo Nuutila.   

Abstract

Decrease in adiponectin level, a common feature in patients with type 2 diabetes mellitus, is considered to predict cardiovascular events. Elevated oxidized low-density lipoprotein (oxLDL), formed within the arterial wall, is commonly seen as part of the atherogenic profile. We investigated the association of adiponectin and oxLDL in 58 patients with type 2 diabetes mellitus and ischemic coronary artery disease. In addition to adiponectin, the serum lipid profile (including oxLDL), plasminogen activator inhibitor 1, high-sensitivity C-reactive protein, and whole-body glucose uptake determined by euglycemic-hyperinsulinemic clamp were evaluated. The average adiponectin level was 7.1 +/- 3.5 microg/mL and was higher in female than in male patients (P = .011). Adiponectin level correlated with whole-body glucose uptake (P = .037) and high-density lipoprotein (HDL) cholesterol concentration (P = .007) and was inversely associated with oxLDL (P = .005), triglycerides (P = .010), and plasminogen activator inhibitor 1 (P = .004). No association was found between adiponectin and high-sensitivity C-reactive protein or LDL cholesterol levels. In multiple linear regression analysis, adiponectin contributed to oxLDL concentration, whereas total cholesterol, LDL and HDL cholesterol, and triglycerides did not. In conclusion, our results suggest that low adiponectin concentration indicates increased oxidative state in the arterial wall, which further supports previous data on the role of adipose tissue in atherogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17570246     DOI: 10.1016/j.metabol.2007.01.018

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  15 in total

Review 1.  Protective vascular and myocardial effects of adiponectin.

Authors:  Barry J Goldstein; Rosario G Scalia; Xin L Ma
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2008-11-25

2.  Simvastatin-induced changes in circulating oxidized low-density lipoprotein in different types of dyslipidemia.

Authors:  Anna Tavridou; Apostolos Efthimiadis; Ioannis Efthimiadis; Vangelis G Manolopoulos
Journal:  Heart Vessels       Date:  2010-07-31       Impact factor: 2.037

Review 3.  Adiponectin serum level in chronic hepatitis C infection and therapeutic profile.

Authors:  Valentina Peta; Carlo Torti; Natasa Milic; Alfredo Focà; Ludovico Abenavoli
Journal:  World J Hepatol       Date:  2015-01-27

4.  Relationship between adipocytokines and cardiovascular risk factors in patients with type 2 diabetes mellitus.

Authors:  Sema Uslu; Nur Kebapçi; Mehmet Kara; Cengiz Bal
Journal:  Exp Ther Med       Date:  2012-04-23       Impact factor: 2.447

5.  Relationship between hydrogen sulfide levels and HDL-cholesterol, adiponectin, and potassium levels in the blood of healthy subjects.

Authors:  Sushil K Jain; David Micinski; Benjamin J Lieblong; Tommie Stapleton
Journal:  Atherosclerosis       Date:  2012-09-10       Impact factor: 5.162

6.  Epidemiologic evidence on serum adiponectin level and lipid profile.

Authors:  Vajihe Izadi; Elaheh Farabad; Leila Azadbakht
Journal:  Int J Prev Med       Date:  2013-02

7.  The association between adiponectin, HDL-cholesterol and α1-antitrypsin-LDL in female subjects without metabolic syndrome.

Authors:  Kazuhiko Kotani; Toshiyuki Yamada; Nobuyuki Taniguchi
Journal:  Lipids Health Dis       Date:  2010-12-30       Impact factor: 3.876

8.  Reduced plasma adiponectin levels relative to oxidized low density lipoprotein and nitric oxide in coronary artery disease patients.

Authors:  Gholam Basati; Morteza Pourfarzam; Ahmad Movahedian; Saed Ziaaldin Samsamshariat; Nizal Sarrafzadegan
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

9.  Effects of pitavastatin on plasminogen activator inhibitor-1 in hyperlipidemic patients.

Authors:  Shosaku Nomura; Takehito Taniura; Akira Shouzu; Seitarou Omoto; Norihito Inami; Shinya Fujita; Takeshi Tamaki; Takashi Yokoi; Toshiki Shimizu; Tomoki Ito
Journal:  Int J Gen Med       Date:  2012-06-18

10.  Consuming a Protein and Fiber-Based Supplement Preload Promotes Weight Loss and Alters Metabolic Markers in Overweight Adults in a 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Erin L Glynn; Stephen A Fleming; Caitlyn G Edwards; Michael J Wilson; Malkanthi Evans; Heather J Leidy
Journal:  J Nutr       Date:  2022-06-09       Impact factor: 4.687

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.